Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II

American Heart Journal
Christie M BallantyneJoel S Raichlen

Abstract

National Cholesterol Education Program Adult Treatment Panel III guidelines for patients at a high risk of coronary heart disease set a low-density lipoprotein cholesterol (LDL-C) target of < 100 mg/dL. This target can be difficult to attain with diet and current therapy. In a 16-week multinational trial, 1993 high-risk patients were randomized to rosuvastatin 20 mg, atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or simvastatin 40 mg for 8 weeks. Patients either remained on starting treatment or switched to lower or milligram-equivalent doses of rosuvastatin for 8 more weeks. At 16 weeks, more patients achieved their LDL-C target by switching to rosuvastatin 10 mg than staying on atorvastatin 10 mg (66% vs 42%, P < .001) or simvastatin 20 mg (73% vs 32%, P < .001). Changing to rosuvastatin 20 mg brought more patients to their LDL-C target than staying on atorvastatin 20 mg (79% vs 64%, P < .001) or simvastatin 40 mg (84% vs 56%, P < .001). More very high risk patients achieved an LDL-C target of < 70 mg/dL when changed to rosuvastatin from atorvastatin or simvastatin (within-arm comparisons P < .01). More hypertriglyceridemic patients (triglycerides > or = 200 mg/dL) met LDL-C, non-high-density lipoprotein cholester...Continue Reading

References

Dec 18, 2002·American Heart Journal·Anders G OlssonUNKNOWN Rosuvastatin Investigators Group
Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Apr 13, 2004·American Heart Journal·Herbert SchusterUNKNOWN Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group
Oct 7, 2004·The American Journal of Cardiology·James ShepherdHoward G Hutchinson

❮ Previous
Next ❯

Citations

Jun 17, 2008·Cardiovascular Drugs and Therapy·Fergus McTaggart, Peter Jones
Mar 12, 2011·Journal of Cardiovascular Translational Research·Zhu ChenAmy M Flattery
Feb 19, 2009·International Journal of Clinical Practice·M RizzoN K Kapur
Nov 26, 2010·International Journal of Clinical Practice·T A Jacobson
Feb 26, 2009·Molecular Cancer Therapeutics·Antonella SassanoLeonidas C Platanias
Aug 3, 2007·Kidney & Blood Pressure Research·Bengt FellströmUNKNOWN AURORA Study Group
Sep 1, 2011·Therapeutic Advances in Chronic Disease·Michel P Hermans, Jean-Charles Fruchart
Dec 22, 2010·Lipids in Health and Disease·Krishnaswami Vijayaraghavan
Apr 8, 2011·Clinical Interventions in Aging·Sydney B LongErin D Michos
May 14, 2009·Vascular Health and Risk Management·Paolo RubbaMarco Gentile
Mar 20, 2015·Journal of Medical Economics·Pedro A LairesGlenn Davies
Mar 7, 2007·Expert Review of Cardiovascular Therapy·Navin K Kapur
Mar 28, 2008·Expert Opinion on Drug Metabolism & Toxicology·John R Crouse
Oct 18, 2011·Expert Opinion on Drug Safety·Peter P Toth, Thomas D Dayspring
Jul 29, 2008·Current Medical Research and Opinion·Sandrin C BergheanuJ Wouter Jukema
Sep 16, 2014·Current Medical Research and Opinion·Khalid Al-RasadiMahmoud Alawadhi
Feb 18, 2014·Journal of Clinical Lipidology·Meredith KilgoreRobert S Rosenson
Mar 2, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Francesca CorteseMarco Matteo Ciccone
May 4, 2010·Mayo Clinic Proceedings·Charles R Harper, Terry A Jacobson
May 20, 2009·Clinical Biochemistry·Helena VaverkovaJiri Frohlich
Jun 24, 2009·Atherosclerosis·Robert S Rosenson
Oct 22, 2008·The American Journal of Cardiology·Philip Barter, Henry N Ginsberg
Mar 21, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·D J Betteridge, J M Gibson
Jul 29, 2010·Clinical Physiology and Functional Imaging·L Vladimirova-KitovaB Marinov
Mar 25, 2008·The American Journal of Cardiology·Michael MillerErnst J Schaefer
Oct 7, 2006·Current Medical Research and Opinion·Alberico L CatapanoAndrew M Tershakovec
Aug 2, 2008·Expert Opinion on Pharmacotherapy·Handrean Soran, Paul Durrington
Apr 26, 2015·Journal of Clinical Lipidology·Terry A JacobsonW Virgil Brown
May 29, 2012·International Journal of Cardiology·Gianluigi SavaresePasquale Perrone-Filardi
May 4, 2012·Journal of Pharmacy Practice·Jennifer SanteeHeather Pace
Nov 22, 2014·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Mar 12, 2015·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Jan 8, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jennifer J KiserDorie W Hoody
Jan 29, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michael S KostapanosMoses S Elisaf

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.